61 results on '"Veelken, Hendrik"'
Search Results
2. Multifocal Extranodal Mucosa-Associated Lymphoid Tissue Lymphoma Affecting the Larynx.
- Author
-
Arndt, Susan, Veelken, Hendrik, Schmitt-Gräff, Annette, Aschendorff, Antje, Maier, Wolfgang, and Richter, Bernhard
- Subjects
- *
LYMPHOMAS , *LYMPHOID tissue , *LARYNX , *HELICOBACTER pylori infections , *MAGNETIC resonance imaging , *ANTIBIOTICS - Abstract
Objectives: Extranodal marginal B-cell lymphoma of mucosa-associated lymphoid tissue (MALT) accounts for about 7% to 8% of all B-cell lymphomas and 50% of all gastric lymphomas. Long-term localized growth is typical of MALT lymphoma. Multifocal manifestations are possible in advanced stages. MALT lymphoma of the larynx is a very rare disease; only 15 cases have been reported in the literature. Methods: We report a case of multifocal MALT lymphoma affecting the larynx associated with extraesophageal reflux, chronic laryngitis, and gastric Helicobacter pylori infection. The staging revealed a recurrent tumor of MALT lymphoma in the stomach and an involvement of the right conjunctiva. Results: Following recent reports on successful treatment of MALT lymphoma with antibiotics, initial empirical therapy with doxycycline calcium led to a subjective clinical symptom improvement but no objective response as assessed by laryngoscopy, magnetic resonance imaging of the larynx, and esophagogastroduodenal endoscopy. Because of the advanced stage and multiple extranodal manifestations of the MALT lymphoma, the patient received 3 cycles of chemoimmunotherapy according to the FCR protocol (fludarabine phosphate-cyclophosphamide-rituximab). No evidence of disease was observed after a 6-month follow-up. Conclusions: In the rare diagnosis of MALT lymphoma of the larynx, comprehensive staging is indispensable to exclude multifocal involvement. In contrast to the treatment of primarily localized MALT lymphoma, multifocal disease warrants systemic therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2007
- Full Text
- View/download PDF
3. Active immunotherapy of multiple myeloma
- Author
-
Houet, Leonora and Veelken, Hendrik
- Subjects
- *
IMMUNITY , *ANTIGENS , *IMMUNOGLOBULINS , *MULTIPLE myeloma - Abstract
Abstract: Since myeloma cells express various potential target antigens, active immunotherapy is being investigated as a novel treatment modality for myeloma. Immunization against the clonal myeloma immunoglobulin (idiotype) elicits protective immunity in mouse models. Idiotype vaccination of myeloma patients can induce cellular immunity, albeit as yet without firm evidence for improved clinical outcome. Other tumour-associated antigens (including cancer/testis antigens) are expressed with various frequencies in myeloma. T cells with specificity for these antigens may exist in myeloma patients, and immunization trials with some of these antigens are ongoing. Future studies need to identify the best antigen, the optimal vaccine formulation and schedule, and the preferable clinical situation for vaccination with myeloma antigens. In addition, immunization of stem cell donors with myeloma antigens may improve the efficacy and outcome of allogeneic stem cell transplantation through transfer of idiotype-directed immunity to the patient, and has already shown promising clinical results. [Copyright &y& Elsevier]
- Published
- 2006
- Full Text
- View/download PDF
4. Active immunotherapy in follicular lymphoma
- Author
-
Veelken, Hendrik
- Subjects
- *
LYMPHOMAS , *ANTIGENS , *ANTI-idiotypic vaccines , *IMMUNOTHERAPY - Abstract
The antigen receptors expressed by follicular lymphomas represent tumor-specific antigens (“idiotypes”). In murine models, vaccination with tumor-derived idiotype in a variety of formulations can induce protective lymphoma-specific immunity. Phase II clinical trials in follicular lymphoma have also demonstrated idiotype-specific immune responses. Clinical data from these trials indicate sustained progression-free survival, disappearance of minimal residual disease, and even frank lymphoma regression in some cases. Phase III trials to prove the beneficial effects of active immunotherapy are currently being conducted. Additional research efforts focus on the most efficacious vaccination route and on the development of convenient methods to manufacture individual idiotype vaccines. [Copyright &y& Elsevier]
- Published
- 2003
- Full Text
- View/download PDF
5. Vaccination Strategies in the Treatment of Lymphomas.
- Author
-
Veelken, Hendrik and Osterroth, Frank
- Subjects
- *
LYMPHOMAS , *RETICULOENDOTHELIAL granulomas , *VACCINATION , *IMMUNIZATION , *IMMUNOTHERAPY , *ANTIGENS - Abstract
Malignant lymphomas are clonal neoplasms of lymphoid origin. By definition, all cells of the malignant clone have undergone the same rearrangement of antigen receptor genes and express identical antigen receptor molecules (immunoglobulin for B cell lymphomas, T cell receptor for T cell lymphomas). The hypervariable stretches within the variable regions of these receptors are considered true tumor-specific antigens (‘idiotypes’). In several animal models, protective humoral or cellular immunity can be induced against the malignant lymphoma by vaccination with the tumor-derived idiotype. Successful experimental immunization strategies in animals include idiotype protein vaccines combined with various adjuvants, genetically or immunologically modified lymphoma cells, idiotype-presenting dendritic cells, idiotype-encoding viral vectors, and DNA immunization. Firm evidence for the induction of lymphoma-specific immunity has also been obtained from human idiotype vaccination trials. Furthermore, some trials have provided strong but hitherto formally unproven evidence for clinical benefit of idiotype-vaccinated patients. Alternative vaccination approaches are based on immunologically modified tumor cells. Current research efforts concentrate on the identification of the most efficacious vaccination route, on definitive proof of clinical efficacy, and on the development of convenient methods to manufacture individual idiotype vaccines.Copyright © 2002 S. Karger AG, Basel [ABSTRACT FROM AUTHOR]
- Published
- 2002
- Full Text
- View/download PDF
6. The degree of HLA matching determines the incidence of cytokine release syndrome and associated nonrelapse mortality in matched related and unrelated allogeneic stem cell transplantation with post-transplant cyclophosphamide.
- Author
-
von dem Borne, Peter A., Kemps-Mols, Berit M., de Wreede, Liesbeth C., van Beek, Adriaan A., Snijders, Tjeerd J.F., van Lammeren, Daniëlle, Tijmensen, Janneke, Sijs-Szabó, Aniko, Oudshoorn, Mirjam A., Halkes, Constantijn J.M, van Balen, Peter, Marijt, W.A. Erik, Tjon, Jennifer M.L., Vermaat, Joost S.P, and Veelken, Hendrik
- Abstract
AbstractCytokine release syndrome (CRS) occurs frequently after haplo-identical allogeneic stem cell transplantation (alloSCT) with post-transplant cyclophosphamide (PTCy), increasing nonrelapse mortality (NRM) and decreasing survival. Data on CRS in HLA-matched alloSCT are limited and effects of specific HLA-mismatches on CRS development unknown. We hypothesized that in HLA-matched alloSCT increasing degrees of HLA-mismatching influence CRS incidence, NRM and survival. Retrospective analysis of 126 HLA-matched PTCy-alloSCT patients showed that higher degrees of HLA-mismatching significantly increased CRS incidence (26%, 75% and 90% CRS with 12/12, 10/10 and 9/10 matched donors, respectively). Maximum temperature during CRS increased with higher HLA-mismatch. Specific associations between HLA-mismatches and CRS could be determined. Grade 2 CRS and CRS-induced grade 3 fever were associated with significantly increased NRM (
p < 0.001 andp = 0.003, respectively) and inferior survival (p < 0.001 andp = 0.005, respectively). NRM was mainly caused by disease conditions that may be considered CRS-induced inflammatory responses (encephalopathy, cryptogenic organizing pneumonia and multi-organ failure). [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF
7. Detection of Low-Level Tumor Cells in Allergic Contact Dermatitis Induced by Mechlorethamine in Patients with Mycosis Fungoides.
- Author
-
Veelken, Hendrik, Sklar, Jeffrey L., and Wood, Gary S.
- Subjects
- *
CONTACT dermatitis , *TUMORS , *MYCOSIS fungoides , *T cell receptors , *POLYMERASE chain reaction , *DENATURING gradient gel electrophoresis , *RIBONUCLEASES , *PATIENTS - Abstract
Two patients with histologically proven mycosis fungoides, a malignancy of phenotypically mature T cells, received a topical challenge with mechlorethamine to areas of clinically uninvolved skin to exclude possible hypersensitivity reactions to this chemotherapeutic agent. In both patients, allergic contact dermatitis (ACD) developed at the sites of the application and resolved completely after withdrawal of mechlorethamine. The lesions were biopsied and analyzed for the presence of clonal T-cell receptor (TCR)-γ gene rearrangements using two polymerase chain reaction (PCR)-based assays involving denaturing gradient gel electrophoresis (PCR/DGGE) and ribonuclease protection analysis (PCR/RPA). The former method has a clonal detection threshold of 10-3-10-2, while the latter has a sensitivity of 10-5. In both cases, the ACD lesions were polyclonal by PCR/ DGGE. In contrast, PCR/RPA detected tumor-specific TCR-γ gene rearrangements in these same lesions. This indicates that the ACD lesions contained tumor cells at a density within the 10-5-102 range. Analysis of peripheral blood mononuclear cells from both patients failed to detect the malignant done and showed the same result as blood from four normal individuals. The normal skin from one patient also lacked detectable TCR-γ gene rearrangements. These results Indicate that mycosis fungoides tumor cells are present within ACD lesions Induced In mycosis fungoides patients and that this phenomenon does not appear to be due to the ubiquitous presence of detectable levels of these tumor cells in the blood or skin. These findings might be explained by nonspecific recruitment of malignant T cells to sites of local inflammation mediated by non-neoplastic antigen-specific T cells. Alternatively, they might be due to the local proliferation of very rare tumor cells in apparently normal skin in response to cytokines generated during the ACD reaction. In either case, the present study offers evidence that the malignant cells in mycosis fungoides retain at least some capability of responding in vivo to physiologic stimuli. [ABSTRACT FROM AUTHOR]
- Published
- 1996
- Full Text
- View/download PDF
8. Molecular Staging of Cutaneous T-Cell Lymphoma: Evidence for Systemic Involvement in Early Disease.
- Author
-
Veelken, Hendrik, Wood, Gary S., and Sklar, Jeffrey
- Subjects
- *
LYMPHOMAS , *T-cell receptor genes , *POLYMERASE chain reaction , *RIBONUCLEASES , *POLYMERIZATION , *GENES - Abstract
Biopsies of various tissues from eight patients with confirmed cutaneous T-cell lymphoma were analyzed for lymphomatous involvement using V-J junctional sequences in rearranged T-cell receptor-γ genes as specific molecular markers for the malignant clone, The patients included one stage IA, one stage IB, and six stage IVA. Twenty-five specimens were analyzed including 14 skin, five lymph node, four blood, and two bone-marrow samples. Ten skin samples and four lymph node samples were histologically positive for lymphoma. The other specimens were morphologically uninvolved. An assay involving polymerase chain reaction (PCR) amplification of T-cell receptor-γ gene rearrangements and denaturing gradient gel electrophoresis was used to identify the tissue specimen containing the greatest tumor clone density in each case. This specimen was then used to generate a tumor-specific RNA probe that was used to molecularly stage each patient by means of an assay involving PCR gene amplification and RNase protection analysis (PCR/RPA). This assay detected malignant cells in all available biopsies, including morphologically uninvolved extracutaneous tissue samples (two blood, one lymph node, and one bone marrow) obtained from the two patients in pathologic stage I. Microscopic examination and the less sensitive PCR/denaturing gradient gel electrophoresis technique failed to detect lymphomatous involvement in 11 (44%) and eight (32%) of these 25 specimens, respectively. We conclude that molecular biologic staging using PCR/RPA is able to demonstrate morphologically occult dissemination of cutaneous T-cell lymphona in early disease. In addition, PCR/RPA may be able to monitor tumor response to therapy and detect early recurrence of malignant lymphomas during clinical remission. [ABSTRACT FROM AUTHOR]
- Published
- 1995
- Full Text
- View/download PDF
9. Outcome of allogeneic haematopoietic cell transplantation in eosinophilic disorders: A retrospective study by the chronic malignancies working party of the EBMT.
- Author
-
McLornan, Donal P., Gras, Luuk, Martin, Ivonne, Sirait, Tiarlan, Schroeder, Thomas, Blau, Igor Wolfgang, Kuball, Jürgen, Byrne, Jenny, Collin, Matthew, Stadler, Michael, Desmier, Déborah, Salmenniemi, Urpu, Jindra, Pavel, Mikhailova, Natalia, Lenhoff, Stig, Rifón, Jose, Robin, Marie, Rovira, Montserrat, Veelken, Hendrik, and Sadowska‐Klasa, Alicja
- Subjects
- *
HYPEREOSINOPHILIC syndrome , *CELL transplantation , *GRAFT versus host disease - Abstract
Patients were transplanted with a median time to allo-HCT of 15.1 months (IQR, 9.8-27.9) for CEL, NOS patients, and 22.2 months (IQR, 11.5-55.8; I p i = 0.01) for HES. Helbig et al. reported on 10 patients with CEL, NOS with a median age of 62 (23-73 years), frequently with an aggressive clinical course, five of whom developed acute transformation within two years from the time of diagnosis.6 Here, only one patient in the chronic phase successfully underwent allo-SCT. Keywords: allogeneic stem cell transplant; chronic eosinophilic leukaemia; conditioning; hypereosinophilic syndrome; non-relapse mortality EN allogeneic stem cell transplant chronic eosinophilic leukaemia conditioning hypereosinophilic syndrome non-relapse mortality 209 213 5 06/27/22 20220701 NES 220701 Hypereosinophilic syndrome (HES) and chronic eosinophilic leukaemia (CEL), not otherwise specified (NOS) are rare haematological disorders.1 Allogeneic haematopoietic cell transplantation (allo-HCT) has been reported in single case reports or small case series only for both refractory HES or CEL, NOS and outcomes remain ill-defined.1-3 HES normally demonstrates a male predominance, likely underrecognized, with a variable clinical course. [Extracted from the article]
- Published
- 2022
- Full Text
- View/download PDF
10. Synchronous diffuse large B-cell lymphoma and mantle cell lymphoma: support for low-threshold biopsies and genetic testing.
- Author
-
de Groot, Fleur A., de Haan, Lorraine M., de Groen, Ruben A. L., Heijmen, Linda, van Wezel, Tom, van Eijk, Ronald, Bohmer, Lara, Bot, Freek, ten Berge, Rosita L., Diepstra, Arjan, Veelken, Hendrik, Cleven, Arjen H. G., Jansen, Patty M., and Vermaat, Joost S. P.
- Subjects
- *
MANTLE cell lymphoma , *DIFFUSE large B-cell lymphomas , *GENETIC testing , *B cell lymphoma - Abstract
The differential intensity of FDG-avid lesions, along with acute and chronic symptoms and iron deficiency anemia caused by intestine involvement, was suspect for distinct disease entities, and consequently the axilla and colon lesions were biopsied. The intensity PET-CT projection showed multiple lesions with varying maximum standardized uptake values (SUVmax), indicating that these lesions reflect different disease entities (Figure 1(A,B)). These two lesions were biopsied and it has been assumed that these represent all other lesions with comparable FDG-avidity because taking more biopsies is not patient friendly, clinically inefficient and the chances of having a third synchronous lymphoma are negligibly small. The presented unique case demonstrated this individualized approach for both lymphoma subtypes and anatomical sites by adjuvant radiotherapy of the axillary PET avid lesions and the initiation of LR for the persistent MCL bowel lesions. [Extracted from the article]
- Published
- 2022
- Full Text
- View/download PDF
11. Interleukin-2-Based Biochemotherapy for Patients with Stage IV Melanoma: Long-Term Survivors Outside a Clinical Trial Setting.
- Author
-
Hess, Viviane, Herrmann, Richard, Veelken, Hendrik, and Schwabe, Michael
- Subjects
- *
INTERLEUKIN-2 , *DRUG therapy , *MELANOMA , *IMMUNOMODULATORS , *INTERLEUKINS - Abstract
Background: The role of Interleukin-2 (IL-2)-based biochemotherapy (BCT) for patients with metastatic melanoma remains controversial and few data of patients treated outside a specialized trial setting are available. Methods: Sixty-six consecutive patients treated with BCT for stage IV melanoma were analyzed retrospectively. All patients received BCT consisting of dacarbazine, cisplatin and vinblastine (CVD), interferon alfa-2a (IFN), and IL-2. IL-2 was administered at two different dose levels: 3 × 106 U/m2/day (BCT-3) and 9 × 106 U/m2/day (BCT-9), each intravenously on 4 consecutive days (days 5–8, 17–20, 26–29). Results: Nine of 66 patients achieved a complete (CR) and 11 patients a partial response (PR), resulting in an overall response rate of 30%. Five responses (2 CR and 3 PR) were observed in the 29 patients treated according to the BCT-3 protocol, 15 responses (7 CR and 8 PR) in the 37 patients treated according to the more IL-2 dose-intense BCT-9 protocol (17 vs. 41%; p = 0.033). Median overall survival (OS) for all 66 patients was 10 (range 3–119+) months. Responders had a superior OS than nonresponders (14 vs. 7 months, p < 0.001). After a median follow-up of 70 months, 5 patients are alive. Among them, 4 are in stable CR at 30+, 48+, 79+ and 119+ months, respectively, amounting to a disease-free survival rate of 6% (4/66). Conclusions: Long-term disease-free survival for patients with stage IV melanoma can be achieved with BCT outside a highly specialized clinical trial setting. Better selection criteria are needed in order to avoid the unnecessary toxic treatment of the majority of patients. Copyright © 2008 S. Karger AG, Basel [ABSTRACT FROM AUTHOR]
- Published
- 2007
- Full Text
- View/download PDF
12. CACTUS: integrating clonal architecture with genomic clustering and transcriptome profiling of single tumor cells.
- Author
-
Shafighi, Shadi Darvish, Kiełbasa, Szymon M., Sepúlveda-Yáñez, Julieta, Monajemi, Ramin, Cats, Davy, Mei, Hailiang, Menafra, Roberta, Kloet, Susan, Veelken, Hendrik, van Bergen, Cornelis A.M., and Szczurek, Ewa
- Subjects
- *
B cell receptors , *CACTUS , *B cells , *RNA sequencing , *EXOMES , *CLONE cells , *SOURCE code , *IMMUNOGLOBULIN class switching - Abstract
Background: Drawing genotype-to-phenotype maps in tumors is of paramount importance for understanding tumor heterogeneity. Assignment of single cells to their tumor clones of origin can be approached by matching the genotypes of the clones to the mutations found in RNA sequencing of the cells. The confidence of the cell-to-clone mapping can be increased by accounting for additional measurements. Follicular lymphoma, a malignancy of mature B cells that continuously acquire mutations in parallel in the exome and in B cell receptor loci, presents a unique opportunity to join exome-derived mutations with B cell receptor sequences as independent sources of evidence for clonal evolution. Methods: Here, we propose CACTUS, a probabilistic model that leverages the information from an independent genomic clustering of cells and exploits the scarce single cell RNA sequencing data to map single cells to given imperfect genotypes of tumor clones. Results: We apply CACTUS to two follicular lymphoma patient samples, integrating three measurements: whole exome, single-cell RNA, and B cell receptor sequencing. CACTUS outperforms a predecessor model by confidently assigning cells and B cell receptor-based clusters to the tumor clones. Conclusions: The integration of independent measurements increases model certainty and is the key to improving model performance in the challenging task of charting the genotype-to-phenotype maps in tumors. CACTUS opens the avenue to study the functional implications of tumor heterogeneity, and origins of resistance to targeted therapies. CACTUS is written in R and source code, along with all supporting files, are available on GitHub (https://github.com/LUMC/CACTUS). [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
13. Template-switching anchored polymerase chain reaction reliably amplifies functional lambda light chain transcripts of malignant lymphoma.
- Author
-
Koning, Marvyn T., Nteleah, Valeri, Veelken, Hendrik, and Navarrete, Marcelo A.
- Subjects
- *
POLYMERASE chain reaction , *LYMPHOMAS , *LYMPHATIC diseases , *ANTIGENS , *GENETIC transcription , *IMMUNOGLOBULINS - Abstract
The article discusses research which was conducted to investigate whether template-switching anchored polymerase chain reaction (PCR) reliably amplifies functional lambda light chain transcripts of malignant lymphoma. Researchers used an alternative approach to current strategies for analysis of immunoglobulin transcripts that did not rely on the use of multiplex PCR to amplify the rearranged variable regions of antigen receptor loci. They found that their strategy was able to amplify the light chain transcripts of malignant lymphoma.
- Published
- 2014
- Full Text
- View/download PDF
14. Effect of alemtuzumab-based T-cell depletion on graft compositional change in vitro and immune reconstitution early after allogeneic stem cell transplantation.
- Author
-
Roex, Marthe C.J., Wijnands, Charissa, Veld, Sabrina A.J., van Egmond, Esther, Bogers, Lisette, Zwaginga, Jaap J., Netelenbos, Tanja, von dem Borne, Peter A., Veelken, Hendrik, Halkes, Constantijn J.M., Falkenburg, J.H. Frederik, and Jedema, Inge
- Subjects
- *
ALEMTUZUMAB , *STEM cell transplantation , *SUPPRESSOR cells , *T cells , *GRAFT versus host disease , *STEM cells , *GRANULOCYTES , *BUSULFAN - Abstract
To reduce the risk of graft-versus-host disease (GVHD) after allogeneic stem cell transplantation (alloSCT), T-cell depletion (TCD) of grafts can be performed by the addition of alemtuzumab (ALT) "to the bag" (in vitro) before transplantation. In this prospective study, the authors analyzed the effect of in vitro incubation with 20 mg ALT on the composition of grafts prior to graft infusion. Furthermore, the authors assessed whether graft composition at the moment of infusion was predictive for T-cell reconstitution and development of GVHD early after TCD alloSCT. Sixty granulocyte colony-stimulating factor-mobilized stem cell grafts were obtained from ≥9/10 HLA-matched related and unrelated donors. The composition of the grafts was analyzed by flow cytometry before and after in vitro incubation with ALT. T-cell reconstitution and incidence of severe GVHD were monitored until 12 weeks after transplantation. In vitro incubation of grafts with 20 mg ALT resulted in an initial median depletion efficiency of T-cell receptor (TCR) α/β T cells of 96.7% (range, 63.5–99.8%), followed by subsequent depletion in vivo. Graft volumes and absolute leukocyte counts of grafts before the addition of ALT were not predictive for the efficiency of TCR α/β T-cell depletion. CD4pos T cells were depleted more efficiently than CD8pos T cells, and naive and regulatory T cells were depleted more efficiently than memory and effector T cells. This differential depletion of T-cell subsets was in line with their reported differential CD52 expression. In vitro depletion efficiencies and absolute numbers of (naive) TCR α/β T cells in the grafts after ALT incubation were not predictive for T-cell reconstitution or development of GVHD post- alloSCT. The addition of ALT to the bag is an easy, fast and generally applicable strategy to prevent GVHD in patients receiving alloSCT after myeloablative or non-myeloablative conditioning because of the efficient differential depletion of donor-derived lymphocytes and T cells. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
15. HLA-Matched Unrelated Donors for Patients with Sickle Cell Disease: Results of International Donor Searches.
- Author
-
Tozatto-Maio, Karina, Torres, Margareth Afonso, Degaide, Neifi Hassan Saloum, Cardoso, Juliana Fernandes, Volt, Fernanda, Pinto, Ana Cristina Silva, Oliveira, Danielli, Elayoubi, Hanadi, Kashima, Simone, Loiseau, Pascale, Veelken, Hendrik, Ferster, Alina, Cappelli, Barbara, Rodrigues, Evandra Strazza, Scigliuolo, Graziana Maria, Kenzey, Chantal, Ruggeri, Annalisa, Rocha, Vanderson, Simões, Belinda Pinto, and Tamouza, Ryad
- Subjects
- *
SICKLE cell anemia , *HEMATOPOIETIC stem cell transplantation , *HLA histocompatibility antigens , *ETHNIC groups - Abstract
• Patients with sickle cell disease (SCD) belong to ethnic groups underrepresented in donor registries. • We assessed chances of finding a matched unrelated donor by geographical origin. • Brazilian patients showed a greater genetic admixture than European Society for Blood and Marrow Transplantation patients. • However, chances of having a potential allelic matched unrelated donor were equal in the 2 groups (47%). • Further strategies to improve donor representativity are warranted in the SCD setting. Sickle cell disease (SCD) is the most common inherited hemoglobinopathy. Hematopoietic stem cell transplantation (HCT) is the sole curative therapy for SCD, but few patients will have a matched sibling donor. Patients with SCD are mostly of African origin and thus are less likely to find a matched unrelated donor in international registries. Using HaploStats, we estimated HLA haplotypes for 185 patients with SCD (116 from a Brazilian center and 69 from European Society for Blood and Marrow Transplantation [EBMT] centers) and classified the ethnic origin of haplotypes. Then we assessed the probability of finding an HLA-matched unrelated adult donor (MUD), considering loci A, B, and DRB1 (6/6), in international registries. Most haplotypes were African, but Brazilians showed a greater ethnic admixture than EBMT patients. Nevertheless, the chance of finding at least one 6/6 potential allelic donor was 47% for both groups. Most potential allelic donors were from the US National Marrow Donor Program registry and from the Brazilian REDOME donor registry. Although the probability of finding a donor is higher than previously reported, strategies are needed to improve ethnic diversity in registries. Moreover, predicting the likelihood of having an MUD might influence SCD management. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
16. Prophylactic donor lymphocyte infusion after allogeneic stem cell transplantation in acute leukaemia – a matched pair analysis by the Acute Leukaemia Working Party of EBMT.
- Author
-
Schmid, Christoph, Labopin, Myriam, Schaap, Nicolaas, Veelken, Hendrik, Schleuning, Michael, Stadler, Michael, Finke, Juergen, Hurst, Erin, Baron, Frederic, Ringden, Olle, Bug, Gesine, Blaise, Didier, Tischer, Johanna, Bloor, Adrian, Esteve, Jordi, Giebel, Sebastian, Savani, Bipin, Gorin, Norbert‐Claude, Ciceri, Fabio, and Mohty, Mohamad
- Abstract
Summary: Strategies for relapse prevention after allogeneic transplantation in acute leukaemia are warranted. A registry‐based matched‐pair analysis evaluated the efficacy of prophylactic donor lymphocyte infusion (proDLI). Adults receiving proDLI in complete remission (CR) and controls were pair‐matched for age, diagnosis, cytogenetics, stage, donor, gender, conditioning and T‐cell depletion. Eighty‐nine pairs were identified (median follow‐up: 6.9 years). Within the entire cohort, no difference was observed. However, among patients with high‐risk acute myeloid leukaemia (AML) (unfavourable cytogenetics and/or transplanted beyond first CR), proDLI recipients had improved overall survival (69.8% vs. 40.2% in controls, P = 0.027). ProDLI has moderate efficacy, but can contribute to improved outcome in high‐risk AML. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
17. Mutated nucleophosmin 1 as immunotherapy target in acute myeloid leukemia.
- Author
-
van der Lee, Dyantha I., Reijmers, Rogier M., Honders, Maria W., Hagedoorn, Renate S., de Jong, Rob C. M., Kester, Michel G. D., van der Steen, Dirk M., de Ru, Arnoud H., Kweekel, Christiaan, Bijen, Helena M., Jedema, Inge, Veelken, Hendrik, van Veelen, Peter A., Heemskerk, Mirjam H. M., Falkenburg, J. H. Frederik, Griffioen, Marieke, de Jong, Rob Cm, Kester, Michel Gd, and Heemskerk, Mirjam Hm
- Subjects
- *
ACUTE myeloid leukemia treatment , *PROTEINS , *RESEARCH , *IMMUNIZATION , *GENETIC mutation , *GENETICS , *HLA-B27 antigen , *NUCLEAR proteins , *ANIMAL experimentation , *RESEARCH methodology , *ACUTE myeloid leukemia , *EVALUATION research , *MEDICAL cooperation , *COMPARATIVE studies , *T cells , *PEPTIDES , *MICE - Abstract
The most frequent subtype of acute myeloid leukemia (AML) is defined by mutations in the nucleophosmin 1 (NPM1) gene. Mutated NPM1 (ΔNPM1) is an attractive target for immunotherapy, since it is an essential driver gene and 4 bp frameshift insertions occur in the same hotspot in 30%-35% of AMLs, resulting in a C-terminal alternative reading frame of 11 aa. By searching the HLA class I ligandome of primary AMLs, we identified multiple ΔNPM1-derived peptides. For one of these peptides, HLA-A*02:01-binding CLAVEEVSL, we searched for specific T cells in healthy individuals using peptide-HLA tetramers. Tetramer-positive CD8+ T cells were isolated and analyzed for reactivity against primary AMLs. From one clone with superior antitumor reactivity, we isolated the T cell receptor (TCR) and demonstrated specific recognition and lysis of HLA-A*02:01-positive ΔNPM1 AML after retroviral transfer to CD8+ and CD4+ T cells. Antitumor efficacy of TCR-transduced T cells was confirmed in immunodeficient mice engrafted with a human AML cell line expressing ΔNPM1. In conclusion, the data show that ΔNPM1-derived peptides are presented on AML and that CLAVEEVSL is a neoantigen that can be efficiently targeted on AML by ΔNPM1 TCR gene transfer. Immunotherapy targeting ΔNPM1 may therefore contribute to treatment of AML. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
18. High Mutation Frequency of the PIGA Gene in T Cells Results in Reconstitution of GPI Anchor-/CD52- T Cells That Can Give Early Immune Protection after Alemtuzumab- Based T Cell-Depleted Allogeneic Stem Cell Transplantation.
- Author
-
Loeff, Floris C., Falkenburg, J. H. Frederik, Hageman, Lois, Huisman, Wesley, Veld, Sabrina A. J., van Egmond, H. M. Esther, van de Meent, Marian, von dem Borne, Peter A., Veelken, Hendrik, Halkes, Constantijn J. M., and Jedema, Inge
- Subjects
- *
GENE frequency , *GENETIC mutation , *T cells , *ALEMTUZUMAB , *HEMATOPOIETIC stem cell transplantation , *GRAFT versus host disease , *THERAPEUTICS , *IMMUNOLOGY , *PHYSIOLOGY - Abstract
Alemtuzumab (ALM) is used for T cell depletion in the context of allogeneic hematopoietic stem cell transplantation (alloSCT) to prevent acute graft-versus-host disease and graft rejection. Following ALM-based T cell-depleted alloSCT, relatively rapid recovery of circulating T cells has been described, including T cells that lack membrane expression of the GPI-anchored ALM target Ag CD52. We show, in a cohort of 89 human recipients of an ALM-based T cell-depleted alloSCT graft, that early lymphocyte reconstitution always coincided with the presence of large populations of T cells lacking CD52 membrane expression. In contrast, loss of CD52 expression was not overt within B cells or NK cells. We show that loss of CD52 expression from the T cell membrane resulted from loss of GPI anchor expression caused by a highly polyclonal mutational landscape in the PIGA gene. This polyclonal mutational landscape in the PIGA gene was also found in CD52- T cells present at a low frequency in peripheral blood of healthy donors. Finally, we demonstrate that the GPI-/CD52- T cell populations that arise after ALM-based T cell-depleted alloSCT contain functional T cells directed against multiple viral targets that can play an important role in immune protection early after ALM-based T cell-depleted transplantation. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
19. Distribution and clinical determinants of time‐to‐positivity of blood cultures in patients with neutropenia.
- Author
-
Lambregts, Merel M. C., Warreman, Eva B., Visser, Leo G., de Boer, Mark G., Bernards, Alexandra T., Veelken, Hendrik, von dem Borne, Peter A., and Dekkers, Olaf M.
- Subjects
- *
NEUTROPENIA , *BLOOD microbiology , *EMPIRICAL medicine , *BACTEREMIA , *PATIENTS , *THERAPEUTICS - Abstract
Abstract: Objectives: Blood cultures (BCs) are essential in the evaluation of neutropenic fever. Modern BC systems have significantly reduced the time‐to‐positivity (TTP) of BC. This study explores the probability of bacteraemia when BCs have remained negative for different periods of time. Methods: All adult patients with neutropenia and bacteraemia were included (January 2012‐February 2016). Predictive clinical factors for short (≤16 hours) and long (>24 hours) TTP were determined. The residual probability of bacteraemia was estimated for the scenario of negative BC 24 hours after collection. Results: The cohort consisted of 154 patients, accounting for 190 episodes of bacteraemia. Median age of 61 years, 60.5% were male. In 123 (64.7%) episodes, BC yielded a single Gram‐positive micro‐organism and in 49 (25.8%) a Gram‐negative micro‐organism (median TTP 16.7, 14.5 hours respectively,
P < .01). TTP was ≤24 hours in 91.6% of episodes. Central line‐associated bacteraemia was associated with long TTP. The probability of bacteraemia if BC had remained negative for 24 hours was 1%‐3%. Conclusions: The expected TTP offers guidance in the management of patients with neutropenia and suspected bacteraemia. The knowledge of negative BC can support a change in working diagnosis, and impact clinical decisions as soon as 24 hours after BC collection. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
20. ARTISAN PCR: rapid identification of full-length immunoglobulin rearrangements without primer binding bias.
- Author
-
Koning, Marvyn T., Kiełbasa, Szymon M., Boersma, Vesna, Buermans, Henk P. J., Zeeuw, Sander A. J., Bergen, Cornelis A. M., Cleven, Arjen H. G., Kluin, Philip M., Griffioen, Marieke, Navarrete, Marcelo A., and Veelken, Hendrik
- Subjects
- *
POLYMERASE chain reaction , *IMMUNOGLOBULINS , *B cells , *ANTIGENS , *GENETIC mutation - Abstract
The article focuses on a study regarding the use of polymerase chain reaction (PCR) for rapid identification of full-length immunoglobulin rearrangements without primer binding bias. It mentions that B cells recognize specific antigens by their membrane-bound B-cell receptor (BCR). It also mentions that non-templated point mutations are introduced into BCR genes by somatic hypermutation (SHM).
- Published
- 2017
- Full Text
- View/download PDF
21. Allogeneic stem cell transplantation in patients with atypical chronic myeloid leukaemia: a retrospective study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation.
- Author
-
Onida, Francesco, Wreede, Liesbeth C., Biezen, Anja, Eikema, Diderik‐Jan, Byrne, Jenny L., Iori, Anna P., Schots, Rik, Jungova, Alexandra, Schetelig, Johannes, Finke, Jürgen, Veelken, Hendrik, Johansson, Jan‐Erik, Craddock, Charles, Stelljes, Matthias, Theobald, Matthias, Holler, Ernst, Schanz, Urs, Schaap, Nicolaas, Bittenbring, Jörg, and Olavarria, Eduardo
- Subjects
- *
STEM cell transplantation , *TREATMENT of chronic myeloid leukemia , *HLA histocompatibility antigens , *CHRONIC leukemia , *HISTOCOMPATIBILITY class I antigens - Abstract
Atypical chronic myeloid leukaemia ( aCML) is an aggressive malignancy for which allogeneic haematopoietic stem cell transplantation (allo- HSCT) represents the only curative option. We describe transplant outcomes in 42 patients reported to the European Society for Blood and Marrow Transplantation ( EBMT) registry who underwent allo- HSCT for aCML between 1997 and 2006. Median age was 46 years. Median time from diagnosis to transplant was 7 months. Disease status was first chronic phase in 69%. Donors were human leucocyte antigen ( HLA)-identical siblings in 64% and matched unrelated ( MUD) in 36%. A reduced intensity conditioning was employed in 24% of patients. T-cell depletion was applied in 87% and 26% of transplants from MUD and HLA-identical siblings, respectively. According to the EBMT risk-score, 45% of patients were 'low-risk', 31% 'intermediate-risk' and 24% 'high-risk'. Following allo- HSCT, 87% of patients achieved complete remission. At 5 years, relapse-free survival was 36% and non-relapse mortality ( NRM) was 24%, while relapse occurred in 40%. Patient age and the EBMT score had an impact on overall survival. Relapse-free survival was higher in MUD than in HLA-identical sibling HSCT, with no difference in NRM. In conclusion, this study confirmed that allo- HSCT represents a valid strategy to achieve cure in a reasonable proportion of patients with aCML, with young patients with low EBMT risk score being the best candidates. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
22. Selective graft-versus-leukemia depends on magnitude and diversity of the alloreactive T cell response.
- Author
-
van Bergen, Cornelis A. M., van Luxemburg-Heijs, Simone A. P., de Wreede, Liesbeth C., Eefting, Matthijs, von dem Borne, Peter A., van Balen, Peter, Heemskerk, Mirjam H. M., Mulder, Arend, Claas, Fransiscus H. J., Navarrete, Marcelo A., Honders, Wilhelmina M., Rutten, Caroline E., Veelken, Hendrik, Jedema, Inge, Halkes, Constantijn J. M., Griffioen, Marieke, and Falkenburg, J. H. Frederik
- Subjects
- *
GRAFT versus host disease , *T cells , *LEUKEMIA , *STEM cell transplantation , *MINOR histocompatibility antigens , *PATIENTS - Abstract
Patients with leukemia who receive a T cell-depleted allogeneic stem cell graft followed by postponed donor lymphocyte infusion (DLI) can experience graft-versus-leukemia (GVL) reactivity, with a lower risk of graft-versus-host disease (GVHD). Here, we have investigated the magnitude, diversity, and specificity of alloreactive CD8 T cells in patients who developed GVL reactivity after DLI in the absence or presence of GVHD. We observed a lower magnitude and diversity of CD8 T cells for minor histocompatibility antigens (MiHAs) in patients with selective GVL reactivity without GVHD. Furthermore, we demonstrated that MiHA-specific T cell clones from patients with selective GVL reactivity showed lower reactivity against nonhematopoietic cells, even when pretreated with inflammatory cytokines. Expression analysis of MiHA-encoding genes showed that similar types of antigens were recognized in both patient groups, but in patients who developed GVHD, T cell reactivity was skewed to target broadly expressed MiHAs. As an inflammatory environment can render nonhematopoietic cells susceptible to T cell recognition, prevention of such circumstances favors induction of selective GVL reactivity without development of GVHD. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
23. Spleen Tyrosine Kinase Is Involved in the CD38 Signal Transduction Pathway in Chronic Lymphocytic Leukemia.
- Author
-
Benkisser-Petersen, Marco, Buchner, Maike, Dörffel, Arlette, Dühren-von-Minden, Marcus, Claus, Rainer, Kläsener, Kathrin, Leberecht, Kerstin, Burger, Meike, Dierks, Christine, Jumaa, Hassan, Malavasi, Fabio, Reth, Michael, Veelken, Hendrik, Duyster, Justus, and Zirlik, Katja
- Subjects
- *
CHRONIC lymphocytic leukemia , *PROTEIN-tyrosine kinases , *CD38 antigen , *CELLULAR signal transduction , *CANCER cell proliferation , *CELL receptors , *CANCER immunology - Abstract
The survival and proliferation of CLL cells depends on microenvironmental contacts in lymphoid organs. CD38 is a cell surface receptor that plays an important role in survival and proliferation signaling in CLL. In this study we demonstrate SYK's direct involvement in the CD38 signaling pathway in primary CLL samples. CD38 stimulation of CLL cells revealed SYK activation. SYK downstream target AKT was subsequently induced and MCL-1 expression was increased. Concomitant inhibition of SYK by the SYK inhibitor R406 resulted in reduced activation of AKT and prevented upregulation of MCL-1. Moreover, short-term CD38 stimulation enhanced BCR-signaling, as indicated by increased ERK phosphorylation. CXCL12-dependent migration was increased after CD38 stimulation. Treating CLL cells with R406 inhibited CD38-mediated migration. In addition, we observed marked downregulation of CD38 expression for CLL cells treated with R406 compared to vehicle control. Finally, we observed a clear correlation between CD38 expression on CLL cells and SYK-inhibitor efficacy. In conclusion, our study provides deeper mechanistic insight into the effect of SYK inhibition in CLL. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
24. Selection patterns of B-cell receptors and the natural history of follicular lymphoma.
- Author
-
Scherer, Florian, Burgt, Marlon, Kiełbasa, Szymon M., Bertinetti ‐ Lapatki, Cristina, Dühren von Minden, Marcus, Mikesch, Kristina, Zirlik, Katja, Wreede, Liesbeth, Veelken, Hendrik, and Navarrete, Marcelo A.
- Subjects
- *
LYMPHOMAS , *IMMUNOGLOBULIN class switching , *B cell receptors , *PROGNOSIS , *BIOMARKERS - Abstract
The article focuses on immunoglobulin class switch recombination (CSR) of B-cell receptors (BCR) in follicular lymphoma (FL), particularly on the impact of class switching on a more aggressive FL. Topics discussed include procedure observed in BCR selection, prognostic significance of N-glycosylation sites found in most FL, and BCR as a stable immunobiological feature of FL.
- Published
- 2016
- Full Text
- View/download PDF
25. Long-term survival and late events after allogeneic stem cell transplantation from HLA-matched siblings for acute myeloid leukemia with myeloablative compared to reduced-intensity conditioning: a report on behalf of the acute leukemia working party of European group for blood and marrow transplantation
- Author
-
Shimoni, Avichai, Labopin, Myriam, Savani, Bipin, Volin, Liisa, Ehninger, Gerhard, Kuball, Jurgen, Bunjes, Donald, Schaap, Nicolaas, Vigouroux, Stephane, Bacigalupo, Andrea, Veelken, Hendrik, Sierra, Jorge, Eder, Matthias, Niederwieser, Dietger, Mohty, Mohamad, and Nagler, Arnon
- Subjects
- *
ACUTE myeloid leukemia treatment , *STEM cell transplantation , *GRAFT versus host disease , *HOMOGRAFTS , *LONG-term health care , *THERAPEUTICS - Abstract
Background: Myeloablative (MAC) and reduced-intensity conditioning (RIC) are established approaches for allogeneic stem cell transplantation (SCT) in acute myeloid leukemia (AML). Most deaths after MAC occur within the first 2 years after SCT, while patients surviving leukemia-free for 2 years can expect a favorable long-term outcome. However, there is paucity of data on the long-term outcome (beyond 10 years) and the pattern of late events following RIC due to the relative recent introduction of this approach. Methods: We analyzed long-term outcomes in a cohort of 1423 AML patients, age =50 years, after SCT from HLA-matched siblings, during the years 1997-2005, median follow-up 8.3 years (0.1-17). Results: The 10-year leukemia-free survival (LFS) was 31 % (95CI, 27-35) and 32 % (28-35) after MAC and RIC, respectively (P = 0.57). The 10-year GVHD/ relapse-free survival (GRFS), a surrogate for quality of life was 22 % (18-25) and 21 % (18-24), respectively (P = 0.79). The 10-year non-relapse mortality (NRM) was higher and relapse rate was lower after MAC, throughout the early and late post-transplant course. The 10-year LFS among 584 patients surviving leukemia-free 2 years after SCT was 71 % (65-76) and 73 % (67-78) after MAC and RIC, respectively (P = 0.76). Advanced leukemia at SCT was the major predictor of LFS subsequent to the 2-year landmark. Relapse was the major cause of late death after both regimens; however, NRM and in particular chronic graft-versus-host disease and second cancers were more common causes of late death after MAC. Conclusions: Long-term LFS and GRFS are similar after RIC and MAC. Most events after RIC or MAC occur within the first 2 years after SCT. Patients who are leukemia-free 2 years after SCT can expect similar good subsequent outcome after both approaches. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
26. Analysis of dendritic cell subpopulations in follicular lymphoma with respect to the tumor immune microenvironment.
- Author
-
Chevalier, Nina, Mueller, Michael, Mougiakakos, Dimitrios, Ihorst, Gabriele, Marks, Reinhard, Schmitt-Graeff, Annette, and Veelken, Hendrik
- Subjects
- *
DENDRITIC cells , *T cells , *LYMPH nodes , *IMMUNOHISTOCHEMISTRY , *HAIR follicles - Abstract
The immune cell composition of the follicular lymphoma (FL) tumor microenvironment is increasingly recognized as an important determinant for clinical outcome. Here, we explored frequency and distribution of dendritic cell (DC) subtypes in relation to regulatory T cells (Treg) by immunohistochemistry in lymph node biopsies from patients withde novoFL. We found that neoplastic follicles contained lower DC and higher Treg frequencies than hyperplastic follicles in control lymph nodes. Treg numbers particularly correlated with the subset of conventional CD11c+ DCs. Additionally, both a high intra- to interfollicular ratio of CD11c+ DCs and increased intrafollicular Treg frequencies were associated with decreased overall survival. This suggests that functional interactions between these cells may be relevant for FL progression/recurrence. The presence of CD11c+ DCs in the tumor microenvironment may assist tumor infiltration by Tregs, thus contributing to the suppression of an otherwise beneficial T-cell-dominated FL microenvironment. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
27. Isotype-switched follicular lymphoma displays dissociation between activation-induced cytidine deaminase expression and somatic hypermutation.
- Author
-
Scherer, Florian, Navarrete, Marcelo A., Bertinetti-Lapatki, Cristina, Boehm, Joachim, Schmitt-Graeff, Annette, and Veelken, Hendrik
- Subjects
- *
CYTIDINE deaminase , *GENE expression , *GENETIC mutation , *IMMUNOGLOBULIN class switching , *IMMUNOGLOBULIN genes , *IMMUNOGLOBULIN variable regions - Abstract
In B-cells, activation-induced cytidine deaminase (AID) is required for somatic hypermutation (SHM) and class switch recombination (CSR) of immunoglobulin genes. AID introduces mutations in immunoglobulin variable regions (IGV) during B-cell receptor affinity maturation, but may also introduce aberrant mutations into non-immunoglobulin genes, most commonly BCL6. Follicular lymphoma (FL) B-cells constitutively express AID and undergo CSR, SHM and aberrant SHM. We have studied AID expression, the presence of SHM mutations, CSR, and aberrant SHM in BCL6 in a cohort of 75 FL patients. Whereas IgM-expressing (non-switched) FL were characterized by an expected positive correlation between AID and IGV and BCL6 mutations, isotype-switched FL showed dissociation between AID expression and aberrant SHM, and inverse correlation between SHM and AID expression. Our results unveil two manifest biological subgroups of FL and indicate that the specific dissociation between AID and SHM after isotype switch may correlate with the clinical outcome of this heterogeneous disease. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
28. Thiotepa-based versus total body irradiation-based myeloablative conditioning prior to allogeneic stem cell transplantation for acute myeloid leukaemia in first complete remission: a retrospective analysis from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation
- Author
-
Eder, Sandra, Labopin, Myriam, Arcese, William, Or, Reuven, Majolino, Ignazio, Bacigalupo, Andrea, Rosa, Gennaro, Volin, Liisa, Beelen, Dietrich, Veelken, Hendrik, Schaap, Nicolaas P. M., Kuball, Jurgen, Cornelissen, Jan, Nagler, Arnon, and Mohty, Mohamad
- Subjects
- *
THIOTEPA , *ORGANOTHIOPHOSPHORUS compounds , *TOTAL body irradiation , *GRAFT versus host disease , *STEM cell transplantation , *ACUTE myeloid leukemia , *PATIENTS - Abstract
Thiotepa is an alkylating compound with an antineoplastic and myeloablative activity and can mimic the effect of radiation. However, it is unknown whether this new regimen could safely replace the longestablished ones. This retrospective matched-pair analysis evaluated the outcome of adults with acute myeloid leukaemia in first complete remission who received myeloablative conditioning either with a thiotepa-based (n = 121) or a cyclophosphamide/total body irradiation-based (TBI; n = 358) regimen for allogeneic hematopoietic stem cell transplantation from an HLA-matched sibling or an unrelated donor. With a median follow-up of 44 months, the outcome was similar in both groups. Acute graft-versus-host disease grade II-IV was observed in 25% after thiotepa-containing regimen versus 35% after TBI (P = 0.06). The 2-yr cumulative incidence of chronic graft-versus-host disease was 40.5% for thiotepa and 41% for TBI (P = 0.98). At 2 yrs, the cumulative incidences of non-relapse mortality and relapse incidence were 23.9% (thiotepa) vs. 22.4% (TBI; P = 0.66) and 17.2% (thiotepa) vs. 23.3% (TBI; P = 0.77), respectively. The probabilities of leukaemia-free and overall survival at 2 yrs were not significantly different between the thiotepa and TBI groups, at 58.9% vs. 54.2% (P = 0.95) and 61.4% vs. 58% (P = 0.72), respectively. Myeloablative regimens using combinations including thiotepa can provide satisfactory outcomes, but the optimal conditioning remains unclear for the individual patient in this setting. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
29. High-dose therapy and autologous stem cell transplantation for extra-nodal NK/T lymphoma in patients from the Western hemisphere: a study from the European Society for Blood and Marrow Transplantation.
- Author
-
Fox, Christopher P., Boumendil, Ariane, Schmitz, Norbert, Finel, Herve, Luan, Jian J., Sucak, Gülsan, Blaise, Didier, Finke, Jürgen, Pflüger, Karl-Heinz, Veelken, Hendrik, Gorin, Norbert -Claude, Poiré, Xavier, Ganser, Arnold, Dreger, Peter, and Sureda, Anna
- Subjects
- *
AUTOTRANSPLANTATION , *STEM cell transplantation , *LYMPHOMAS , *DISEASE remission , *PROGRESSION-free survival - Abstract
Extra-nodal NK/T lymphoma (ENKTL) is rare and more frequently encountered in East Asia. The role of high-dose therapy and autologous stem cell transplantation (HDT-ASCT) for ENKTL is unclear. Twenty-eight evaluable patients who had undergone HDT-ASCT in Europe from 2000–2009 were studied. The median age was 47 years and patients had received a median of two lines of prior therapy. Some 57% of patients were not in complete remission or beyond first complete remission at HDT-ASCT. The 1-year non-relapse mortality (NRM) was 11%; 2-year progression-free survival (PFS) and overall survival (OS) rates were 41% and 52%, respectively. Notably, the 2-year PFS and OS for those with stage III/IV disease were 33% and 40%, respectively, with no relapses beyond 1-year post-HDT-ASCT. This is the largest analysis of HDT-ASCT for patients with ENKTL reported from the Western hemisphere. Survival is comparable to East Asian cohorts and outcomes are encouraging for patients with advanced disease. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
30. Higher busulfan dose intensity appears to improve leukemia-free and overall survival in AML allografted in CR2: An analysis from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
- Author
-
Kharfan-Dabaja, Mohamed A., Labopin, Myriam, Bazarbachi, Ali, Socie, Gerard, Kroeger, Nicolaus, Blaise, Didier, Veelken, Hendrik, Bermudez, Arancha, Or, Reuven, Lioure, Bruno, Beelen, Dietrich, Fegueux, Nathalie, Hamladji, Rose Marie, Nagler, Arnon, and Mohty, Mohamad
- Subjects
- *
BUSULFAN , *DRUG dosage , *ACUTE leukemia , *HOMOGRAFTS , *BONE marrow transplantation , *PATIENTS , *LEUKEMIA treatment - Abstract
Allogeneic hematopoietic cell transplantation is a potentially curative treatment in patients with acute myeloid leukemia. Recent advances in the field of hematopoietic cell allografting have resulted in a practice shift, favoring less intense preparative regimens. We present results of a retrospective comparative analysis of two preparative regimens, namely FB2 (IV fludarabine plus IV busulfan 6.4 mg/kg ± 10%) and FB4 (IV fludarabine plus IV busulfan 12.8 mg/kg ±10%), in patients with acute myeloid leukemia undergoing hematopoietic cell allografting in second complete remission at EBMT participating centers. Between 2003 and 2010, 128 AML patients in second complete remission were allografted following a preparative regimen of FB2 ( n = 88) or FB4 ( n = 40). The median time-to-neutrophil engraftment was similar whether patients received FB2 (16 (5–38) days) or FB4 (16 (9–29) days), p = 0.45. A multivariate analysis showed that use of FB4 resulted in improved 2-year leukemia-free (HR = 0.44 (95%CI = 0.21, 0.94), p = 0.03) and overall survival (HR = 0.38 (95%CI = 0.16, 0.86), p = 0.02). Cumulative incidence of non-relapse mortality (2-year) for all patients was 21% (95%CI = 14–28%). Our analysis suggests that FB4 improves 2-year leukemia-free and overall survival in AML allografted in second complete remission. A confirmatory randomized controlled trial that compares these two preparative regimens (FB2 vs. FB4) in AML in CR2 is definitely warranted. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
31. Outcomes of Cord Blood Transplantation Using Reduced-Intensity Conditioning for Chronic Lymphocytic Leukemia: A Study on Behalf of Eurocord and Cord Blood Committee of Cellular Therapy and Immunobiology Working Party, Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation, and the Societé Française de Greffe de Moelle et Therapie Cellulaire
- Author
-
Xavier, Erick, Cornillon, Jérôme, Ruggeri, Annalisa, Chevallier, Patrice, Cornelissen, Jan J., Andersen, Niels S., Maillard, Natacha, Nguyen, Stephanie, Blaise, Didier, Deconinck, Eric, Veelken, Hendrik, Milpied, Noel, Van Gelder, Michel, Peffault de Latour, Regis, Gluckman, Eliane, Kröger, Nicolaus, Schetelig, Johannes, and Rocha, Vanderson
- Subjects
- *
CORD blood transplantation , *TRANSPLANTATION of organs, tissues, etc. , *CHRONIC lymphocytic leukemia , *IMMUNOLOGY , *LYMPHOCYTIC leukemia , *PATIENTS - Abstract
Outcomes after umbilical cord blood transplantation (UCBT) for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) are unknown. We analyzed outcomes of 68 patients with poor-risk CLL/SLL who underwent reduced-intensity (RIC) UCBT from 2004 to 2012. The median age was 57 years and median follow-up 36 months; 17 patients had del 17p/p53mutation, 19 patients had fludarabine-refractory disease, 11 relapsed after autologous stem cell transplantation, 8 had diagnosis of prolymphocytic leukemia, 4 had Richter syndrome, and 8 underwent transplantation with progressive or refractory disease. The most common RIC used was cyclophosphamide, fludarabine, and total body irradiation (TBI) in 82%; 15 patients received antithymocyte globulin. Most of the cord blood grafts were HLA mismatched and 76% received a double UCBT. Median total nucleated cells collected was 4.7 × 10 7 /kg. The cumulative incidences (CI) of neutrophil and platelet engraftment were 84% and 72% at 60 and 180 days respectively; day 100 graft-versus-host disease (GVHD) (grade II to IV) was 43% and 3-year chronic GVHD was 32%. The CI of relapse, nonrelapse mortality, overall survival, and progression-free survival (PFS) at 3 years were 16%, 39%, 54%, and 45%, respectively. Fludarabine-sensitive disease at transplantation and use of low-dose TBI regimens were associated with acceptable PFS. In conclusion, use of RIC-UCBT seems to be feasible in patients with poor-risk CLL/SLL and improved outcomes were observed in patients with fludarabine-sensitive disease who received low-dose TBI regimens. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
32. Lectins from opportunistic bacteria interact with acquired variable-region glycans of surface immunoglobulin in follicular lymphoma.
- Author
-
Schneider, Dunja, Dühren-von Minden, Marcus, Alkhatib, Alabbas, Setz, Corinna, van Bergen, Cornelis A. M., Benkißer-Petersen, Marco, Wilhelm, Isabel, Villringer, Sarah, Krysov, Sergey, Packham, Graham, Zirlik, Katja, Römer, Winfried, Buske, Christian, Stevenson, Freda K., Veelken, Hendrik, and Jumaa, Hassan
- Subjects
- *
LECTINS , *GLYCANS , *LYMPHOMA treatment , *B cells , *ANTIGEN receptors , *AUTOANTIGENS , *IMMUNOGLOBULINS , *GLYCOSYLATION - Abstract
B-cell antigen receptor (BCR) expression is a key feature of most B-cell lymphomas, but the mechanisms of BCR signal induction and the involvement of autoantigen recognition remain unclear. In follicular lymphoma (FL) B cells, BCR expression is retained despite a chromosomal translocation that links the antiapoptotic gene BCL2 to the regulatory elements of immunoglobulin genes, thereby disrupting 1 heavy-chain allele. A remarkable feature of FL-BCRs is the acquisition of potential N-glycosylation sites during somatic hypermutation. The introduced glycans carry mannose termini, which create potential novel binding sites for mannose-specific lectins. Here, we investigated the effect of N-linked variable-region glycosylation for BCR interaction with cognate antigen and with lectins of different origins. N-glycans were found to severely impair BCR specificity and affinity to the initial cognate antigen. In addition, we found that lectins from Pseudomonas aeruginosa and Burkholderia cenocepacia bind and stimulate FL cells. Human exposure to these bacteria can occur by contact with soil and water. In addition, they represent opportunistic pathogens in susceptible hosts. Understanding the role of bacterial lectins might elucidate the pathogenesis of FL and establish novel therapeutic approaches. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
33. Impact of minimal residual disease on outcomes after umbilical cord blood transplantation for adults with Philadelphia-positive acute lymphoblastic leukaemia: an analysis on behalf of Eurocord, Cord Blood Committee and the Acute Leukaemia working party of the European group for Blood and Marrow Transplantation
- Author
-
Tucunduva, Luciana, Ruggeri, Annalisa, Sanz, Guillermo, Furst, Sabine, Cornelissen, Jan, Linkesch, Werner, Mannone, Lionel, Ribera, Josep‐Maria, Veelken, Hendrik, Yakoub‐Agha, Ibrahim, González Valentín, Maria Elvira, Schots, Rik, Arcese, William, Montesinos, Pau, Labopin, Myriam, Gluckman, Eliane, Mohty, Mohamad, and Rocha, Vanderson
- Subjects
- *
HEALTH outcome assessment , *CORD blood transplantation , *HEMATOLOGY , *PUBLIC health research , *MEDICAL care - Abstract
The status of umbilical cord blood transplantation ( UCBT) in adults with Philadelphia-positive acute lymphoblastic leukaemia (Ph+ ALL) and the impact of minimal residual disease ( MRD) before transplant are not well established. We analysed 98 patients receiving UCBT for Ph+ ALL in first ( CR1) or second ( CR2) complete remission ( CR1, n = 79; CR2, n = 19) with MRD available before UCBT (92% analysed by reverse transcription polymerase chain reaction). Median age was 38 years and median follow-up was 36 months; 63% of patients received myeloablative conditioning and 42% received double-unit UCBT. Eighty-three patients were treated with at least one tyrosine kinase inhibitor before UCBT. MRD was negative (−) in 39 and positive (+) in 59 patients. Three-year cumulative incidence of relapse was 34%; 45% in MRD+ and 16% in MRD− patients ( P =0·013). Three-year cumulative incidence of non-relapse mortality was 31%; it was increased in patients older than 35 years ( P = 0·02). Leukaemia-free survival ( LFS) at 3 years was 36%; 27% in MRD+ and 49% in MRD− patients ( P = 0·05), and 41% for CR1 and 14% for CR2 ( P = 0·008). Multivariate analysis identified only CR1 as being associated with improved LFS. In conclusion, MRD+ before UCBT is associated with increased relapse. Strategies to decrease relapse in UCBT recipients with Ph+ ALL and MRD+ are needed. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
34. Vanishing ulnae: symmetrical diffuse large B-cell lymphoma.
- Author
-
Roukens, Anna, Vlasveld, Tom, Veelken, Hendrik, and Kersting, Sabina
- Published
- 2013
- Full Text
- View/download PDF
35. Insulin-like growth factor-1 receptor (IGF1R) as a novel target in chronic lymphocytic leukemia.
- Author
-
Yaktapour, Niuscha, Übelhart, Rudolf, Schüler, Julia, Aumann, Konrad, Dierks, Christine, Burger, Meike, Pfeifer, Dietmar, Jumaa, Hassan, Veelken, Hendrik, Brummer, Tilman, and Zirlik, Katja
- Subjects
- *
PROTEIN-tyrosine kinases , *CHRONIC lymphocytic leukemia , *CHRONIC diseases , *PEPTIDES , *HEMATOLOGY , *AMINO acids - Abstract
The receptor tyrosine kinase (RTK) insulin-like growth factor-1 receptor (IGF1R) is implicated in various tumor entities including chronic lymphocytic leukemia (CLL), but its functional significance in this disease remains poorly characterized. Here, we show that the IGF1R protein is overexpressed in various CLL subsets, suggesting a contribution to CLL pathology. Indeed, we show that IGF1R knockdown in primary human CLL cells compromised their viability. Likewise, IGF1R inhibition with 3 structurally distinct compounds induced apoptosis, even in the presence of protective stroma components. Furthermore, IGF1R inhibition effectively limited CLL development in Eμ-TCL1 transgenic mice and of primary human CLL xenografts. In agreement with its prosurvival function, IGF1R inhibition affected the phosphorylation and/or expression of multiple signaling proteins. The multikinase inhibitor sorafenib yielded similar effects on these signaling elements as IGF1R inhibitors. Indeed, IGF1R appears to be a direct sorafenib target because sorafenib decreased IGF1R expression and phosphorylation, counteracted insulin-like growth factor-1 (IGF-1) binding to CLL cells, and lowered the in vitro kinase activity of recombinant, purified IGF1R. Thus, we demonstrate that blockade of IGF1R-mediated signaling represents a novel mechanism of action for sorafenib in CLL. Importantly, IGF1R inhibitors compromise CLL viability in their microenvironment context, implicating this RTK as a promising therapeutic target. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
36. Integration of Mutational Signature Analysis with 3D Chromatin Data Unveils Differential AID-Related Mutagenesis in Indolent Lymphomas.
- Author
-
Sepulveda-Yanez, Julieta H., Alvarez-Saravia, Diego, Fernandez-Goycoolea, Jose, Aldridge, Jacqueline, van Bergen, Cornelis A. M., Posthuma, Ward, Uribe-Paredes, Roberto, Veelken, Hendrik, and Navarrete, Marcelo A.
- Subjects
- *
DNA repair , *LYMPHOMAS , *MUTAGENESIS , *DNA analysis , *CHRONIC lymphocytic leukemia , *FOLLICULAR lymphoma - Abstract
Activation-induced deaminase (AID) is required for somatic hypermutation in immunoglobulin genes, but also induces off-target mutations. Follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL), the most frequent types of indolent B-cell tumors, are exposed to AID activity during lymphomagenesis. We designed a workflow integrating de novo mutational signatures extraction and fitting of COSMIC (Catalogue Of Somatic Mutations In Cancer) signatures, with tridimensional chromatin conformation data (Hi-C). We applied the workflow to exome sequencing data from lymphoma samples. In 33 FL and 30 CLL samples, 42% and 34% of the contextual mutations could be traced to a known AID motif. We demonstrate that both CLL and FL share mutational processes dominated by spontaneous deamination, failures in DNA repair, and AID activity. The processes had equiproportional distribution across active and nonactive chromatin compartments in CLL. In contrast, canonical AID activity and failures in DNA repair pathways in FL were significantly higher within the active chromatin compartment. Analysis of DNA repair genes revealed a higher prevalence of base excision repair gene mutations (p = 0.02) in FL than CLL. These data indicate that AID activity drives the genetic landscapes of FL and CLL. However, the final result of AID-induced mutagenesis differs between these lymphomas depending on chromatin compartmentalization and mutations in DNA repair pathways. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
37. An HLA-A*11:01-Binding Neoantigen from Mutated NPM1 as Target for TCR Gene Therapy in AML.
- Author
-
van der Lee, Dyantha I., Koutsoumpli, Georgia, Reijmers, Rogier M., Honders, Willy, de Jong, Rob C. M., Remst, Dennis F. G., Wachsmann, Tassilo L. A., Hagedoorn, Renate S., Franken, Kees L. M. C., Kester, Michel G. D., Harber, Karl J., Roelofsen, Lisanne M., Schouten, Annemiek M., Mulder, Arend, Drijfhout, Jan W., Veelken, Hendrik, van Veelen, Peter A., Heemskerk, Mirjam H. M., Falkenburg, Frederik, and Griffioen, Marieke
- Subjects
- *
AMINO acid metabolism , *ACUTE myeloid leukemia treatment , *IN vitro studies , *HLA-B27 antigen , *GENETIC mutation , *ANIMAL experimentation , *CELL receptors , *GENE therapy , *TUMOR antigens , *IMMUNOTHERAPY , *MICE - Abstract
Simple Summary: Acute myeloid leukemia (AML) is an aggressive hematological malignancy with poor prognosis. For AML relapses after chemotherapy, new and effective therapies are needed. In 30–35% of AMLs, a frameshift mutation in the nucleophosmin 1 gene (dNPM1) creates potential neoantigens that are attractive targets for immunotherapy. We previously isolated a T-cell receptor (TCR) that targets an HLA-A*02:01-binding dNPM1 neoantigen on primary AML. Here, we investigated whether AVEEVSLRK is another dNPM1 neoantigen that can be targeted by TCR gene transfer. We isolated various T-cells, cloned the HLA-A*11:01-restricted TCR from one T-cell clone and, upon transfer to CD8 cells, demonstrated targeting of dNPM1 primary AMLs in vitro. However, the TCR failed to mediate an anti-tumor effect in immunodeficient mice engrafted with dNPM1 OCI-AML3 cells. Our results demonstrate that AVEEVSLRK is an HLA-A*11:01-binding neoantigen on dNPM1 AML. Whether the isolated TCR is of sufficient affinity to treat patients remains uncertain. Acute myeloid leukemia (AML) is a hematological malignancy caused by clonal expansion of myeloid progenitor cells. Most patients with AML respond to chemotherapy, but relapses often occur and infer a very poor prognosis. Thirty to thirty-five percent of AMLs carry a four base pair insertion in the nucleophosmin 1 gene (NPM1) with a C-terminal alternative reading frame of 11 amino acids. We previously identified various neopeptides from the alternative reading frame of mutant NPM1 (dNPM1) on primary AML and isolated an HLA-A*02:01-restricted T-cell receptor (TCR) that enables human T-cells to kill AML cells upon retroviral gene transfer. Here, we isolated T-cells recognizing the dNPM1 peptide AVEEVSLRK presented in HLA-A*11:01. The TCR cloned from a T-cell clone recognizing HLA-A*11:01+ primary AML cells conferred in vitro recognition and lysis of AML upon transfer to CD8 cells, but failed to induce an anti-tumor effect in immunodeficient NSG mice engrafted with dNPM1 OCI-AML3 cells. In conclusion, our data show that AVEEVSLRK is a dNPM1 neoantigen on HLA-A*11:01+ primary AMLs. CD8 cells transduced with an HLA-A*11:01-restricted TCR for dNPM1 were reactive against AML in vitro. The absence of reactivity in a preclinical mouse model requires further preclinical testing to predict the potential efficacy of this TCR in clinical development. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
38. Usage of standardized antigen-presenting cells improves ELISpot performance for complex protein antigens.
- Author
-
Navarrete, Marcelo A., Bertinetti-Lapatki, Cristina, Michelfelder, Ines, and Veelken, Hendrik
- Subjects
- *
ENZYME-linked immunosorbent assay , *ANTIGENS , *CANCER immunotherapy , *BIOLOGICAL assay , *MONOCYTES , *ANTIGEN presentation , *MACROPHAGES , *OLIGOPEPTIDES - Abstract
Abstract: The enzyme-linked immunospot (ELISpot) assay is a widely used method for immune monitoring in cancer immunotherapy trials. In the ELISpot assay, peripheral blood mononuclear cells (PBMC) are stimulated with specific antigens, and cytokines of interest produced by individual cells are detected. In the standard procedure, T cells rely for antigen presentation on other cells like the monocyte/macrophage population present among the PBMC. Whereas oligopeptides can be added directly to the ELISpot assay without the necessity of a pre-incubation step, protein antigens must be internalized and processed by antigen-presenting cells to accomplish efficient presentation via HLA class I or II. We have studied the impact of sources for different antigen-presenting cell (i.e. PBMC-resident monocytes and monocyte-derived dendritic cells maturated with Poly I:C and PGE-2 based cocktails) on ELISpot assay performance and defined an optimized dendritic cell-based ELISpot protocol. This protocol is suitable for monitoring immune responses directed to protein antigens with higher sensitivity than the standard procedure. [Copyright &y& Elsevier]
- Published
- 2013
- Full Text
- View/download PDF
39. Uptake routes of tumor-antigen MAGE-A3 by dendritic cells determine priming of naïve T-cell subtypes.
- Author
-
Moeller, Ines, Spagnoli, Giulio, Finke, Jürgen, Veelken, Hendrik, and Houet, Leonora
- Subjects
- *
TUMOR antigens , *DENDRITIC cells , *T cells , *CANCER immunotherapy , *MONOCLONAL antibodies , *PHAGOCYTOSIS , *IMMUNE complexes , *PROTEASOME inhibitors - Abstract
Induction of tumor-antigen-specific T cells in active cancer immunotherapy is generally difficult due to the very low anti-tumoral precursor cytotoxic T cells. By improving tumor-antigen uptake and presentation by dendritic cells (DCs), this problem can be overcome. Focusing on MAGE-A3 protein, frequently expressed in many types of tumors, we analyzed different DC-uptake routes after additional coating the recombinant MAGE-A3 protein with either a specific monoclonal antibody or an immune complex formulation. Opsonization of the protein with antibody resulted in increased DC-uptake compared to the uncoated rhMAGE-A3 protein. This was partly due to Fcγ receptor-dependent internalization. However, unspecific antigen internalization via macropinocytosis also played a role. When analyzing DC-uptake of MAGE-A3 antigen expressed in multiple myeloma cell line U266, pretreatment with proteasome inhibitor bortezomib resulted in increased apoptosis compared to γ-irradiation. Bortezomib-mediated immunogenic apoptosis, characterized by elevated surface expression of hsp90, triggered higher phagocytosis of U266 cells by DCs involving specific DC-derived receptors. We further investigated the impact of antigen delivery on T-cell priming. Induction of CD8 T-cell response was favored by stimulating naïve T cells with either antibody-opsonized MAGE-A3 protein or with the bortezomib-pretreated U266 cells, indicating that receptor-mediated uptake favors cross-presentation of antigens. In contrast, CD4 T cells were preferentially induced after stimulation with the uncoated protein or protein in the immune complex, both antigen formulations were preferentially internalized by DCs via macropinocytosis. In summary, receptor-mediated DC-uptake mechanisms favored the induction of CD8 T cells, relevant for clinical anti-tumor response. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
40. Chronic lymphocytic leukaemia is driven by antigen-independent cell-autonomous signalling.
- Author
-
Minden, Marcus Dühren-von, Übelhart, Rudolf, Schneider, Dunja, Wossning, Thomas, Bach, Martina P., Buchner, Maike, Hofmann, Daniel, Surova, Elena, Follo, Marie, Köhler, Fabian, Wardemann, Hedda, Zirlik, Katja, Veelken, Hendrik, and Jumaa, Hassan
- Subjects
- *
LYMPHOCYTIC leukemia , *B cells , *ANTIGEN receptors , *EPITOPES , *CARCINOGENESIS ,WESTERN countries - Abstract
B-cell antigen receptor (BCR) expression is an important feature of chronic lymphocytic leukaemia (CLL), one of the most prevalent B-cell neoplasias in Western countries. The presence of stereotyped and quasi-identical BCRs in different CLL patients suggests that recognition of specific antigens might drive CLL pathogenesis. Here we show that, in contrast to other B-cell neoplasias, CLL-derived BCRs induce antigen-independent cell-autonomous signalling, which is dependent on the heavy-chain complementarity-determining region (HCDR3) and an internal epitope of the BCR. Indeed, transferring the HCDR3 of a CLL-derived BCR provides autonomous signalling capacity to a non-autonomously active BCR, whereas mutations in the internal epitope abolish this capacity. Because BCR expression was required for the binding of secreted CLL-derived BCRs to target cells, and mutations in the internal epitope reduced this binding, our results indicate a new model for CLL pathogenesis, with cell-autonomous antigen-independent signalling as a crucial pathogenic mechanism. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
41. The prognostic value of serum methotrexate area under curve in elderly primary CNS lymphoma patients.
- Author
-
Kasenda, Benjamin, Rehberg, Marcel, Thürmann, Petra, Franzem, Melanie, Veelken, Hendrik, Fritsch, Kristina, Schorb, Elisabeth, Finke, Jürgen, Lebiedz, Dirk, and Illerhaus, Gerald
- Subjects
- *
LYMPHOMAS , *CENTRAL nervous system , *METHOTREXATE , *PHARMACOKINETICS , *PHARMACODYNAMICS , *DRUG therapy , *HEALTH outcome assessment , *PATIENTS - Abstract
Studies on pharmacokinetics and pharmacodynamics of high-dose methotrexate chemotherapy (HD-MTX) in elderly primary central nervous system lymphoma (PCNSL) patients are rare. MTX exposure time has recently been proposed as an outcome determining factor in PCNSL. We investigated 49 immunocompetent PCNSL patients (female N = 30, male N = 19, median age 73 years) who were treated according to HD-MTX-based protocols. A two-compartment pharmacokinetic model was used to describe the MTX clearance. Response to treatment was assessed by MRI. We used multivariable models to investigate the association between MTX exposure and tumor response as well as survival. Dose normalized MTX peak serum levels [ C, μmol/L g] and dose normalized area under the curve [AUC, μmol h/L g] were higher in females than in males, respectively [59.4 (f) vs. 48.1 (m), P < 0.001; 373.2 (f) vs. 271.9 (m), P = 0.008]. Increasing AUC was inversely correlated with tumor response. AUC values above 2,126 h μmol/L were independently associated with shorter overall and progression-free survival [hazard ratio (HR), 4.56, 95 % CI 1.74-11.94; HR 2.87, 95 % CI 1.18-7.00]. Exceedingly high MTX AUC levels can have a negative impact on progression-free and overall survivals in elderly PCNSL patients. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
42. Serum Level of CC-Chemokine Ligand 18 Is Increased in Patients with Non-Small-Cell Lung Cancer and Correlates with Survival Time in Adenocarcinomas.
- Author
-
Plönes, Till, Krohn, Alexander, Burger, Meike, Veelken, Hendrik, Passlick, Bernward, Müller-Quernheim, Joachim, and Zissel, Gernot
- Subjects
- *
CANCER patients , *TUMORS , *CARCINOGENS , *ADENOCARCINOMA , *ADENOID cystic carcinoma - Abstract
CC-chemokinelig and 18 (CCL18) is mainly expressed by alternatively activated macrophages and DCs and plays an important role in lung fibrosis, arthritis and other diseases. HereCCL18 was measured in sera of 31healthy volunteers and 170 patients with lung cancer and correlated these data with histology, tumor stage and clinical parameters. Mean CCL 18 serum level of the patients with non-small-cell lung cancer was 150(857) ng/ml vs. 32(61) ng/ml in the healthy control group. Patient groups differ significantly according the irhistology (adenocarcinoma143(528) ng/mlvs squamous cell carcinoma187(857)ng/ml,p<0.02). In addition, we found a significant difference between patients with lower versus higher T-stage (p<0.003). Receiver operating characteristic (ROC) analyses revealed a cut off point of 83 ng/ml (area under the curve (AUC):0.968;p<0.0001) to discriminate between healthy controls and non-small-cell lung cancer patients. ROC analyses to discriminate between patients, who died because of cancer related death and those who died for other reasons did not lead to a valid AUC. To stratify the tumor patients, acriterion value plot Was performed leading to a point of equal sensitivity and specificity (54%) of 162 ng/ml. Patients with aCCL18serum level higher than 160 ng/ml had a mean survival time of 623 days. In contrast, those in patients with a baseline level between 83 ng/ml and 160 ng/ml the mean survival timewas984days (p<0.005). Survival-analysis revealed in a denocarcinoma a mean survival of1152 days in the group below 83 ng/ml. In the median group the mean survival time was 788 days and in the group with the highest levels the mean survival time was 388 days (p<0.001). In contrast, we found no correlation between the FEV1 and the CCL18 baseline level. In conclusion, in patients suffering from adenocarcinoma increased serum CCL18 levels predict a diminished survival time. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
43. Trisomy 12 and elevated GLI1 and PTCH1 transcript levels are biomarkers for Hedgehog-inhibitor responsiveness in CLL.
- Author
-
Decker, Sarah, Zirlik, Katja, Djebatchie, Lauritte, Hartmann, David, Ihorst, Gabriele, Schmitt-Graett, Annette, Herchenbach, Dieter, Jumaa, Hassan, Warmuth, Markus, Veelken, Hendrik, and Dierks, Christine
- Subjects
- *
CHRONIC lymphocytic leukemia treatment , *TRISOMY , *LYMPHOCYTIC leukemia , *LIGANDS (Biochemistry) , *KARYOTYPES , *AUTOCRINE mechanisms - Abstract
Hedgehog (HH) signaling is activated in various lymphoid malignancies, but conflicting results exist about its role in chronic lymphocytic leukemia (CLL). Here, we demonstrate that the expression of essential HH pathway components like GLI1, PTCH1, and the HH ligands is highly diverse in CLL. A subset of 36.7% of 60 tested CLL samples responded to all 3 SMOOTHENED (SMO) inhibitors, whereas 40% were completely resistant. Responsiveness correlated with elevated GLII and PTCH1 transcript levels and the presence of trisomy 12, whereas no other karyotype correlated with responsiveness. All trisomy 12 CLLs displayed constitutive HH pathway activation driven by autocrine DESERT HH (DHH) ligand secretion, which could be blocked by the HH-blocking Ab 5E1. Cocultures with DHH-expressing BM stromal cells reduced sensitivity of CLLs to SMO- inhibitor treatment by activation of noncanonical ERK phosphorylation directly downstream of the PTCH1 receptor without involvement of SMO and could be overcome by the H H-blocking Ab 5E1 or a combination of SMO and ERK inhibitors. Our results demonstrate that the HH-signaling pathway is an interesting therapeutic target for a subset of patients with CLL, characterized by high GLI1 and PTCH1 transcript levels, and all patients with trisomy 12 and indicate HH-blocking Abs to be favorable over SMO inhibitors in overcoming stroma-mediated protective effects. (Blood. 2012;119(4):997-1 007) [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
44. Horse versus rabbit antithymocyte globulin in aplastic anemia.
- Author
-
Halkes CJ, Veelken H, Falkenburg JH, Halkes, Constantijn J M, Veelken, Hendrik, and Falkenburg, J H Frederik
- Published
- 2011
- Full Text
- View/download PDF
45. B-cell receptor epitope recognition correlates with the clinical course of chronic lymphocytic leukemia.
- Author
-
Binder, Mascha, Müller, Fabian, Jackst, Antje, Léchenne, Barbara, Pantic, Milena, Bacher, Ulrike, zu Eulenburg, Christine, Veelken, Hendrik, Mertelsmann, Roland, Pasqualini, Renata, Arap, Wadih, and Trepel, Martin
- Subjects
- *
CHRONIC lymphocytic leukemia , *B cells , *CELL receptors , *PEPTIDES , *EPITOPES - Abstract
BACKGROUND: B-cell receptors (BCRs) and their recognition of specific epitopes may play a pivotal role in the development and progression of chronic lymphocytic leukemia (CLL). In this study, the authors set up a model system to explore epitope reactivity and its clinical relevance in CLL. METHODS: Epitope-mimicking peptides were selected from phage display libraries on 6 CLL BCRs from randomly chosen patients. The binding of the 6 index epitope mimics was evaluated in a set of 100 unrelated CLL samples. Epitope recognition patterns were correlated with the clinical course of the disease. RESULTS: Surprisingly, all CLL samples recognized 1 or several index epitopes, and some revealed marked polyreactivity. Patients with CLL who expressed BCRs that reacted with ≥5 epitope mimics had a significantly worse clinical course than less polyreactive patients (median time to first treatment, 24 months vs 102 months). This effect was independent of otherwise known prognostic markers. CONCLUSIONS: The authors introduced a system with which to model epitope reactivity of CLL BCRs without previous knowledge of potential antigens. The findings indicated that a polyreactive epitope recognition pattern may be a determinant of an aggressive clinical course in this disease. This further emphasizes the functional and prognostic relevance of BCR epitope recognition in CLL. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
46. Control of the specificity of T cell-mediated anti-idiotype immunity by natural regulatory T cells.
- Author
-
Warncke, Max, Buchner, Maike, Thaller, Gudrun, Dodero, Anna, Bulashevska, Alla, Pfeifer, Dietmar, Timmer, Jens, and Veelken, Hendrik
- Subjects
- *
B cell lymphoma , *T cells , *IMMUNOREGULATION , *DENDRITIC cells , *CELL proliferation , *HEMAGGLUTININ , *ANTINEOPLASTIC agents , *GENE expression - Abstract
The idiotypes of B cell lymphomas represent tumor-specific antigens. T cell responses induced by idiotype vaccination in vivo are directed predominantly against CDR peptides, whereas in vitro T cells also recognize framework-derived epitopes. To investigate the mechanisms regulating the specificity of idiotype-specific T cells, BALB/c or B10.D2 mice were immunized with mature dendritic cells loaded with H-2K-restricted peptides from influenza hemagglutinin, or from shared (J region) or unique (CDR3) structures of the A20 lymphoma idiotype. Antigen-specific T cells were induced in vivo by the CDR3 and influenza epitopes, but not by the J peptide. Gene expression profiling of splenic regulatory T cells revealed vaccination-induced Treg activation and proliferation. Treg activity involved J epitope-dependent IL-10 secretion and functional suppression of peptide-specific effector T cells. Vaccination-induced in vivo proliferation of transgenic hemagglutinin-specific T cells was suppressed by co-immunization with the J peptide and was restored in CD25-depleted animals. In conclusion, Treg induced by a shared idiotype epitope can systemically suppress T cell responses against idiotype-derived and immunodominant foreign epitopes in vivo. The results imply that tumor vaccines should avoid epitopes expressed by normal cells in the draining lymph node to achieve optimal anti-tumor efficacy. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
47. The microenvironment differentially impairs passive and active immunotherapy in chronic lymphocytic leukaemia - CXCR4 antagonists as potential adjuvants for monoclonal antibodies.
- Author
-
Buchner, Maike, Brantner, Philipp, Stickel, Natalie, Prinz, Gabriele, Burger, Meike, Bär, Constance, Dierks, Christine, Pfeifer, Dietmar, Ott, Ariane, Mertelsmann, Roland, Gribben, John G., Veelken, Hendrik, and Zirlik, Katja
- Subjects
- *
IMMUNOTHERAPY , *CHRONIC lymphocytic leukemia , *MONOCLONAL antibodies , *MESENCHYMAL stem cells , *KILLER cells , *DRUG resistance , *CHEMOKINES - Abstract
Summary Direct contact with stromal cells protects chronic lymphocytic leukaemia (CLL) B cells from chemotherapy-induced apoptosis in vitro. Blockade of CXCR4 signalling antagonizes stroma-mediated interactions and restores CLL chemosensitivity. In vivo, administration of CXCR4 antagonists effectively mobilizes haematopoietic progenitor cells. Therefore, combinations of CXCR4 blockade and cytoreductive treatment with selective activity on CLL cells may avoid potential haematotoxicity. Hence, we tested CXCR4 antagonists in the context of passive and active immunotherapeutic approaches. We evaluated how efficiently rituximab, alemtuzumab and cytotoxic T cells killed CLL cells cocultured with stromal cells in the presence and absence of a CXCR4 antagonist. Stromal cell contact attenuated rituximab- and alemtuzumab-induced complement-dependent cytotoxicity of CLL cells. Addition of CXCR4 antagonists abrogated the protective effect of stroma. In contrast, stromal cells did not impair antibody-dependent cell-mediated cytotoxicity and cytotoxicity induced by activated T cells. Destruction of microtubules in CLL target cells restored the protective effect of stroma coculture for CLL cells during Natural Killer cell attack by preventing mitochondrial relocalization towards the immunological synapse. Our data identify the combination of CXCR4 antagonists with passive - but not active - immunotherapy as a promising potential treatment concept in CLL. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
48. Expansion of NKG2A−LIR1− Natural Killer Cells in HLA-Matched, Killer Cell Immunoglobulin-Like Receptors/HLA-Ligand Mismatched Patients following Hematopoietic Cell Transplantation
- Author
-
Rathmann, Silvia, Glatzel, Sabine, Schönberg, Kathrin, Uhrberg, Markus, Follo, Marie, Schulz-Huotari, Christian, Kaymer, Markus, Veelken, Hendrik, Finke, Jürgen, and Fisch, Paul
- Subjects
- *
KILLER cells , *HLA histocompatibility antigens , *HEMATOPOIETIC stem cells , *CELL transplantation , *IMMUNOGLOBULINS , *MEMBRANE proteins , *LECTINS , *HOMOGRAFTS - Abstract
The prognosis after hematopoietic cell transplantation (HCT) for the treatment of leukemia or lymphoma in humans is influenced by donor-derived natural killer (NK) cells, which enhance the graft-versus-leukemia (GVL) effect. Such alloreactive killer cells can be generated in vivo after HCT if the donor expresses killer cell immunoglobulin-like receptors (KIRs), such as KIR2DL1, KIR2DL2/3, or KIR3DL1, for which the recipient lacks HLA class I ligands. We studied effector cells from 22 KIR/HLA-ligand mismatched and 14 KIR/HLA-ligand matched, primarily HLA-matched patient-donor pairs after allogeneic HCT. A novel 8-color flow cytometry panel allowed us to characterize effector-cell populations without “broadly reactive” inhibitory receptors such as CD94/NKG2A or LIR1. The numbers of such NKG2A– LIR1– NK cells increased following HCT in patients transplanted by KIR/HLA-ligand mismatched grafts, compared to KIR/HLA-ligand matched grafts, and in patients transplanted from donors of the A/B, compared to A/A, KIR haplotypes. NKG2A–LIR1– NK cells expressing only those inhibitory KIRs for which the patient had no HLA class I ligands could be stimulated by HLA class I-deficient cells to express CD107a. Thus, NKG2A–LIR1– NK cells may be important GVL effector cells following HCT, even in patients transplanted from HLA-matched donors. [Copyright &y& Elsevier]
- Published
- 2010
- Full Text
- View/download PDF
49. CCL19 is a specific ligand of the constitutively recycling atypical human chemokine receptor CRAM-B.
- Author
-
Leick, Marion, Catusse, Julie, Follo, Marie, Nibbs, Robert J., Hartmann, Tanja N., Veelken, Hendrik, and Burger, Meike
- Subjects
- *
MACROPHAGES , *LIGANDS (Biochemistry) , *LYMPHATICS , *CHEMOKINES , *IMMUNOGLOBULINS , *DENDRITIC cells - Abstract
The human chemokine receptor CRAM (chemokine receptor on activated macrophages), encoded by the gene CCRL2, is a new candidate for the atypical chemokine receptor family that includes the receptors DARC, D6 and chemocentryx chemokine receptor (CCX-CKR). CRAM is maturation-stage-dependently expressed on human B lymphocytes and its surface expression is up-regulated upon short-term CCL5 exposure. Here, we demonstrate that the homeostatic chemokine CCL19 is a specific ligand for CRAM. In radioactive labelling studies CCL19 bound to CRAM-expressing cells with an affinity similar to the described binding of its other receptor CCR7. In contrast to the known CCL19/CCR7 ligand/receptor pair, CRAM stimulation by CCL19 did not result in typical chemokine-receptor-dependent cellular activation like calcium mobilization or migration. Instead, we demonstrate that CRAM is constitutively recycling via clathrin-coated pits and able to internalize CCL19 as well as anti-CRAM antibodies. As this absence of classical chemokine receptor responses and the recycling and internalization features are characteristic for non-classical chemokine receptors, we suggest that CRAM is the newest member of this group. As CCL19 is known to be critically involved in lymphocyte and dendritic cell trafficking, CCL19-binding competition by CRAM might be involved in modulating these processes. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
50. A Homozygous CARD9 Mutation in a Family with Susceptibility to Fungal Infections.
- Author
-
Glocker, Erik-Oliver, Hennigs, Andre, Nabavi, Mohammad, Schäffer, Alejandro A., Woellner, Cristina, Salzer, Ulrich, Pfeifer, Dietmar, Veelken, Hendrik, Warnatz, Klaus, Tahami, Fariba, Jamal, Sarah, Manguiat, Annabelle, Rezaei, Nima, Amirzargar, Ali Akbar, Plebani, Alessandro, Hannesschläger, Nicole, Gross, Olaf, Ruland, Jürgen, and Grimbacher, Bodo
- Subjects
- *
CANDIDIASIS , *CANDIDA , *GENETICS , *MYCOSES , *GENES , *INFECTION , *GENETIC mutation , *PATIENTS - Abstract
Background: Chronic mucocutaneous candidiasis may be manifested as a primary immunodeficiency characterized by persistent or recurrent infections of the mucosa or the skin with candida species. Most cases are sporadic, but both autosomal dominant inheritance and autosomal recessive inheritance have been described. Methods: We performed genetic studies in 36 members of a large, consanguineous five-generation family, in which 4 members had recurrent fungal infections and an additional 3 members died during adolescence, 2 after invasive infection of the brain with candida species. All 36 family members were enrolled in the study, and 22 had blood samples taken for DNA analysis. Homozygosity mapping was used to locate the mutated gene. In the 4 affected family members (patients) and the 18 unaffected members we sequenced CARD9, the gene encoding the caspase recruitment domain-containing protein 9, carried out T-cell phenotyping, and performed functional studies, with the use of either leukocytes from the patients or a reconstituted murine model of the genetic defect. Results: We found linkage (lod score, 3.6) to a genomic interval on chromosome 9q, including CARD9. All four patients had a homozygous point mutation in CARD9, resulting in a premature termination codon (Q295X). Healthy family members had wild-type expression of the CARD9 protein; the four patients lacked wild-type expression, which was associated with low numbers of Th17 cells (helper T cells producing interleukin-17). Functional studies based on genetic reconstitution of myeloid cells from Card9 mice showed that the Q295X mutation impairs innate signaling from the antifungal pattern-recognition receptor dectin-1. Conclusions: An autosomal recessive form of susceptibility to chronic mucocutaneous candidiasis is associated with homozygous mutations in CARD9. N Engl J Med 2009;361:1727-35. [ABSTRACT FROM AUTHOR]
- Published
- 2009
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.